# Alcohol Withdrawal Management

## I. General Considerations

- **Intubated patients**: If receiving a propofol or midazolam infusion, **no additional therapy** is required while on these infusions.
- **Excluded patients**:
    * On essential medications that interact with phenobarbital (e.g., HIV medications)
    * Hepatic encephalopathy
    * Chronic phenobarbital use
    * Pregnant

---

## II. Vitamin Supplementation (All Patients)

- Thiamine 100 mg PO/PT/IV daily × 3 days
- Folic acid 1 mg PO/PT daily × 3 days
- Multivitamin PO/PT daily × 3 days

---

## III. Risk Stratification & Management

### A. Low Risk \*
- Phenobarbital 60 mg PO TID × 6 doses
- Then: Phenobarbital 30 mg PO TID × 6 doses

### B. High Risk \*\*
- Phenobarbital 130 mg PO q1h × 2 doses  
  If unable to take PO: Phenobarbital 260 mg IV ×1
- Then:
    * 100 mg PO TID × 6 doses
    * 60 mg PO TID × 6 doses
    * 30 mg PO TID × 6 doses

### C. Active Delirium Tremens (DTs)
- Phenobarbital 260 mg IV × 1 dose
- Then:
    * 100 mg PO TID × 6 doses
    * 60 mg PO TID × 6 doses
    * 30 mg PO TID × 6 doses
- If symptoms uncontrolled → Consider SICU transfer

---

## IV. Additional Information

- **PO dosing preferred** unless:
    * Acute symptom management required
    * Lack of enteral access
    * Patient unable to swallow safely  
  _PO:IV conversion = 1:1_

- **Breakthrough withdrawal symptoms** despite taper:
    * Phenobarbital 65 mg IV q1h PRN to goal RASS 0 to -1
    * Hold dose if RASS ≤ -2 or RR ≤ 12 → notify provider

- Avoid **benzodiazepines**

### Dose Considerations
- Soft max cumulative dose: 20 mg/kg (IBW)
- Absolute max cumulative dose: 30 mg/kg (IBW)
    * Patients with IBW < 70 kg may need adjusted taper

- If symptoms persist after 20 mg/kg:
    * Consider alternate diagnoses
    * Additional phenobarbital dosing should be cautious
    * Consult Addiction Psychiatry

- If total dose reaches 30 mg/kg → Do **not** give more phenobarbital

---

## V. Alcohol Withdrawal Presentation

### A. Signs and Symptoms
- Nausea/vomiting
- Tremor
- Paroxysmal sweating
- Tachycardia (> 100 bpm)
- Hypertension
- Anxiety/agitation
- Visual, tactile, or auditory hallucinations
- Clouded sensorium
- Seizures

> **Note**: Symptoms may begin within 6–48 hours of alcohol cessation and may progress to DTs if untreated.

### B. Delirium Tremens (DTs)

- DTs = alcohol withdrawal symptoms **plus** acute delirium
- Occurs in ~5% of patients
- Presents typically at 48–72 hours, can occur up to 96 hours after last drink

**Symptoms include:**
- Tachycardia
- Hypertension
- Fevers
- Increased respiratory rate / respiratory alkalosis
- Hallucinations (visual/auditory)
- Marked agitation

> - Symptoms may last up to **5 days**  
> - Untreated mortality may reach **15%**, primarily from **aspiration risk**  
> - **Airway protection** should be considered in patients with DTs

---

## VI. Risk Stratification Notes

\* **Low Risk**:
- Positive Audit C
- No history of DTs or alcohol withdrawal seizures

\*\* **High Risk**:
- History of alcohol withdrawal seizures
- History of DTs
- BAC > 200
- BAC > 100 **plus** symptoms of withdrawal

---

## VII. Authors

**Jennifer Beavers, PharmD, BCPS**  
**Bradley M. Dennis, MD**  
*February 26, 2024*

---

## VIII. References

1. Tidwell WP, Thomas TL, Pouliot JD, et al. _Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-AR protocol._ **Am J Crit Care** 2018;27(6):454–460.  
2. Nisavic MD, Nejad SH, Isenberg BM, et al. _Use of phenobarbital in alcohol withdrawal management._ **Psychosomatics.** 2019;60(5):458–467.  
3. Oks M, Cleven KL, Healy L, et al. _Phenobarbital for severe AWS in the MICU._ **J Intensive Care Med.** 2018.  
4. Ammar MA, et al. _Phenobarbital Monotherapy for AWS in Surgical-Trauma Patients._ **Ann Pharmacother.** 2021;55(3):294–302. doi:10.1177/1060028020949137.  
5. Kodadek LM, et al. _Alcohol-Related Trauma Reinjury Prevention._ **J Trauma Acute Care Surg.** 2020;88(1):106–112.  
6. Fleenor LM, et al. _Phenobarbital vs Benzodiazepine for AWS in trauma patients._ **J Trauma Acute Care Surg.** 2024 Mar;96(3):493–498. PMID: 37599414.
